We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

316 hedge funds and large institutions have $2.06B invested in Recursion Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 86 funds opening new positions, 114 increasing their positions, 62 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more first-time investments, than exits

New positions opened: 86 | Existing positions closed: 34

84% more repeat investments, than reductions

Existing positions increased: 114 | Existing positions reduced: 62

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

18% more funds holding

Funds holding: 267 → 316 (+49)

18% more capital invested

Capital invested by funds: $1.74B → $2.06B (+$317M)

1% less call options, than puts

Call options by funds: $30.7M | Put options by funds: $30.9M

14.8% less ownership

Funds ownership: 94.22% → 79.42% (-15%)

Holders
316
Holders Change
+49
Holders Change %
+18.35%
% of All Funds
4.16%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
86
Increased
114
Reduced
62
Closed
34
Calls
$30.7M
Puts
$30.9M
Net Calls
-$211K
Net Calls Change
+$8.19M

Top Buyers

1
SoftBank Group
SoftBank Group
Japan
+$98.6M
2
NHAS
Novo Holdings A/S
Denmark
+$68M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$65.5M
4
BlackRock
BlackRock
New York
+$18.1M
5
Citadel Advisors
Citadel Advisors
Florida
+$16.8M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$51.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.68M
3
Voloridge Investment Management
Voloridge Investment Management
Florida
-$6.42M
4
NAMA
Nikko Asset Management Americas
New York
-$5.29M
5
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
-$5.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$230M +$65.5M +9,737,196 +40%
AIM
2
ARK Investment Management
Florida
$219M -$2.84M -422,788 -1%
Baillie Gifford & Co
3
Baillie Gifford & Co
United Kingdom
$168M -$2.53M -375,812 -1%
BlackRock
4
BlackRock
New York
$158M +$18.1M +2,693,839 +13%
SoftBank Group
5
SoftBank Group
Japan
$99.2M +$98.6M +14,667,491 New
MIC
6
Mubadala Investment Company
United Arab Emirates
$87.8M – – –
State Street
7
State Street
Massachusetts
$85M -$1.96M -291,912 -2%
KA
8
Kinnevik AB
Sweden
$80.5M – – –
NHAS
9
Novo Holdings A/S
Denmark
$68.4M +$68M +10,114,633 New
MCMU
10
MIC Capital Management (UK)
United Kingdom
$65.2M +$8.02M +1,192,275 +14%
Sumitomo Mitsui Trust Group
11
Sumitomo Mitsui Trust Group
Japan
$60.7M -$5.29M -786,127 -8%
NAMA
12
Nikko Asset Management Americas
New York
$60.1M -$5.29M -786,127 -8%
RCM
13
RA Capital Management
Massachusetts
$52.2M -$51.5M -7,659,519 -50%
NC
14
Nvidia Corp
California
$52.1M – – –
Fidelity Investments
15
Fidelity Investments
Massachusetts
$47.8M -$8.68M -1,291,349 -15%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$41.2M +$4.41M +655,238 +12%
DCI
17
Data Collective IV
California
$40.2M – – –
DOFI
18
DCVC Opportunity Fund II
California
$26.7M – – –
LIM
19
Lingotto Investment Management
United Kingdom
$24.8M – – –
Norges Bank
20
Norges Bank
Norway
$23.4M -$717K -106,681 -3%
UBS Group
21
UBS Group
Switzerland
$20.3M +$14.8M +2,204,785 +276%
Morgan Stanley
22
Morgan Stanley
New York
$19.3M +$6.61M +983,326 +52%
Citadel Advisors
23
Citadel Advisors
Florida
$18.5M +$16.8M +2,505,024 +1,070%
LCM
24
Laurion Capital Management
New York
$16.6M +$16.5M +2,457,189 New
Northern Trust
25
Northern Trust
Illinois
$16.2M +$2.5M +371,886 +18%
1
2 3 4 5

RXRX Hedge Fund Activity: Q4 2024 in Review

316 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2024, worth a combined $2.06B — up 18% from $1.74B a quarter earlier.

Buyers outnumbered sellers: 86 funds opened new RXRX positions and 34 closed out — a net gain of 52 holders — while 114 added to existing stakes and 62 trimmed.

The largest buyer was SoftBank Group, opening a new position worth an estimated $98.6M. The largest seller was RA Capital Management, cutting an estimated $51.5M.

  • 316 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2024, up from 267 in Q3 2024.
  • Funds reported $2.06B of Recursion Pharmaceuticals stock for Q4 2024, up 18% quarter-over-quarter.
  • 86 funds opened new Recursion Pharmaceuticals positions in Q4 2024 and 34 closed out, a net change of +52 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2024 was SoftBank Group, an estimated $98.6M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2024 was RA Capital Management, an estimated $51.5M sold.

Based on aggregated 13F filings for Q4 2024.